Close Menu

NEW YORK (GenomeWeb) – Veracyte said it has priced its public offering of 5.5 million shares of its common stock at $23.25 per share. It expects gross proceeds of $127.9 million.

Veracyte said earlier this week that it plans to use the proceeds for working capital and other purposes, including to repay around $12.4 million of its term loan.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.